SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Friedrich Nietzsche

PatientFriedrich Nietzsche
Date of birth1989-10-15
IdentifiersMRN HR-NI019-SYN; SSN (made up) 000-19-5523
Document date2026-09-15
AuthorKonrad Ellison-Mbatha, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Eight-week review of migraine prevention after the withdrawal. [S]

History of Present Illness

Mr. Nietzsche returns eight weeks after starting galcanezumab and five weeks after the last butalbital tablet. His diary shows 7 headache days in the past four weeks, 4 with migraine features, and no attack lasting more than a day. He used acute medicine on 5 days: sumatriptan on 3, with relief within two hours in 2, and naproxen on 2. He has taken no combination tablets. The injections cause only brief redness, and his constipation is unchanged. The floaters in his right eye have nearly gone, with no new flashes. He sleeps about six hours after five CBT-I sessions. His mood is good. His HIV, hepatitis C and hepatitis B tests from the preventive visit were negative, and he was told by phone. He is writing for several hours on most days and walking as before. [S]

ElementDetail
Headache days7 in the past four weeks, 4 with migraine features (from about 20 and 12 before treatment)
Acute medicine5 days: sumatriptan on 3, naproxen on 2
DisabilityMIDAS 31 (grade IV), from 74; HIT-6 58, from 68
MoodPHQ-9 4; GAD-7 3
SleepAbout six hours
Screening resultsHIV, hepatitis C and hepatitis B negative

Review of Systems

SystemResultFinding
EyesNegativeFloaters nearly gone; no flashes, shadow or distortion on the Amsler grid
GastrointestinalNegativeNo nausea between attacks; constipation unchanged
NeurologicalPositiveSeven headache days in four weeks; no new features
PsychiatricNegativeMood good; PHQ-9 4

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, one or two tablets as needed for headache, taken on about 16 days a month, up to four tablets a day (prescribed abroad)One or two tablets as needed, about 16 days a month, up to four a dayOral route2025-11-03 to 2026-07-21stoppedS
Ibuprofen 200 mg oral tablet, two tablets as needed for headache on days without the combination tablets, about 4 days a month (over the counter)Two tablets as needed, about 4 days a monthOral route2025-11-03 to 2026-07-21stoppedS
Butalbital 50 mg, acetaminophen 325 mg and caffeine 40 mg oral tablet, scheduled taper: one tablet twice a day for 7 days, then one tablet a day for 7 days, then one tablet every other day for 7 days, then stopScheduled taper over three weeks: twice a day, then once a day, then every other day, then stop; not for extra dosesOral route2026-07-21 to 2026-08-10completedS
Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a weekOne tablet at attack onset, may repeat once after 12 hours; no more than two days a weekOral route2026-07-21activeS
Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a weekOne tablet with the acute medicine when nausea is present, no more than once a dayOral route2026-07-21activeS
Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine preventionLoading dose of 240 mg (two injections) on the first day, then 120 mg every four weeksSubcutaneous route2026-07-21activeS
Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a monthOne tablet at attack onset, may repeat once after 2 hours; up to 200 mg a day, no more than eight days a monthOral route2026-08-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-15Body height174cmS
2026-09-15Body weight67kgS
2026-09-15Body mass index (BMI) [Ratio]22.1kg/m2S
2026-09-15Systolic blood pressure112mm[Hg]S
2026-09-15Diastolic blood pressure72mm[Hg]S
2026-09-15Heart rate62/minS
2026-09-15Respiratory rate14/minS
2026-09-15Body temperature36.6CelS
2026-09-15Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-15Because of your headaches on how many days in the last 3 months did you miss work or school [PhenX]6dS
2026-09-15Because of your headaches on how many days in the last 3 months was your productivity at work or school reduced by half or more [PhenX]10dS
2026-09-15Because of your headaches on how many days in the last 3 months did you not do household work [PhenX]3dS
2026-09-15Because of your headaches on how many days in the last 3 months was your productivity in house-hold work reduced by half or more [PhenX]5dS
2026-09-15Because of your headaches on how many days in the last 3 months did you miss family, social, or leisure activities [PhenX]7dS
2026-09-15Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-09-15Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S

Physical Exam

Vital signs recorded on 2026-09-15; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 112/72, pulse 62
EyesRepeat dilated examination of the right eye: the vitreous detachment is complete, with no retinal break or detachment; macula unchanged
NeurologicalNormal

Problems

ProblemClinical statusVerificationCodeProvenance
Frequent disabling headaches on about 20 days a month, with nausea, vomiting and light sensitivity, mostly right-sided, since childhood and more frequent over the past year, with a combination headache tablet containing butalbital taken on about 16 days a month; under evaluation with a headache diary, MRI, syphilis serology and a headache medicine consultationresolvedconfirmed R51.9S — Synthetic presenting problem anchored to his documented headaches; superseded when the consultation confirmed chronic migraine with medication overuse headache.
Chronic migraine without aura (15 or more headache days a month for more than three months, at least 8 with migraine features); ICHD-3 criteria met in a two-week diary; MRI of the brain normal; synthetic modern diagnosis linked to his documented headaches, which historians interpret differentlyactiveconfirmed G43.709S — Synthetic modern diagnosis made at the consultation; the historical diagnosis is disputed (CLM-0014), so this is not a claim about his real diagnosis.
Medication overuse headache from a butalbital, acetaminophen and caffeine combination on 10 or more days a month for more than three months, with ibuprofen on other days; resolved after a three-week taper and withdrawalresolvedconfirmed G44.40S — Synthetic diagnosis made at the consultation, anchored to his documented use of many medicines and sedatives; not a claim about his real medicines.
High myopia in both eyes, much worse in the right eye, since early childhood, with long-standing poor vision in the right eye and unequal pupils; comprehensive eye examination bookedactiveconfirmed H52.13S — Synthetic modern coding of his documented severe myopia.
Pathologic (degenerative) myopia of the right eye with patchy chorioretinal atrophy of the macula, a posterior staphyloma and a tilted optic disc; no choroidal neovascularization on OCT; best corrected vision 20/100 in the right eyeactiveconfirmed H44.2E1S — Synthetic finding of the comprehensive eye examination, anchored to his documented poor right eye and the retrospective reading of it as myopic degeneration; not a claim about his real eyes.
Chronic insomnia, with difficulty falling asleep and early waking, worse on headache nights; no sleep medicine at intakeactiveconfirmed G47.00S — Synthetic sleep problem anchored to his documented severe insomnia; not a claim about his real sleep.
Acute posterior vitreous detachment of the right eye, with flashes and a floater, without a retinal break, detachment or vitreous hemorrhage on dilated examination, in an eye with pathologic myopiaresolvedconfirmed H43.811S — Synthetic acute eye problem in a highly myopic eye; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationRed-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive courseEvery visitCompleted todayNo red flags
SurveyHeadache diary: headache days, migraine days, attack features, triggersEvery visitCompleted today7 headache days and 4 migraine days in four weeks
Medication safetyAcute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15)Every visitCompleted todayAcute medicine on 5 days: sumatriptan on 3, naproxen on 2; no combination tablets
Medication safetyGalcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivityBefore starting and at each injection visitCompleted todayBrief redness only; constipation unchanged; blood pressure 112/72; third dose given today
ExaminationPreventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month)At three months on treatmentDueEarly response at eight weeks (migraine days 12 to 4); formal judgment at the three-month review
SurveyDisability (MIDAS, recorded as its five items, and HIT-6)At baseline and after two to three months of treatmentCompleted todayMIDAS items 6, 10, 3, 5 and 7 days, total 31 (grade IV), from 74; the recall includes the weeks before treatment; HIT-6 58, from 68
SurveyMood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harmAt baseline and at two to three months; questions at every visitCompleted todayPHQ-9 4, item 9 scored 0; GAD-7 3
ExaminationDilated re-examination after an acute posterior vitreous detachmentWithin six weeks of the detachment, sooner with new symptomsCompleted todaySix weeks after the detachment: complete, with no retinal break or detachment
ExaminationComprehensive eye examination: refraction, pupils, pressure, dilated fundus examination, macular OCTAt diagnosis, then yearly for pathologic myopia, and urgently for new flashes, floaters or a shadowUp to dateComprehensive examination eight weeks ago; next in one year
Self-managementSleep: hours, sleep diary, insomnia severity; no sedative sleeping tabletsEvery visitCompleted todayAbout six hours after five CBT-I sessions; no sleeping tablets
Self-managementReading, writing and walking planEvery visitCompleted todayWriting several hours a day with breaks; daily walks continue

Goal progress:

Guideline basis: Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018); The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021); Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024); European Academy of Neurology guideline on the management of medication-overuse headache (2020); European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022); Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation (2018); Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013); Refractive Errors Preferred Practice Pattern (2023); Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025); Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Three-month review in four weeks, before he leaves for the winter, with the fourth injection and a plan for care by the sea. Second hepatitis B vaccine dose in two weeks. [S]